| 37.34 Data as of May 17 |  +0.48 / +1.30%Today’s Change | 17.25 Today|||52-Week Range 58.91 | +39.75% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.2B |
Company Description
Questcor Pharmaceuticals, Inc. operates as a biopharmaceutical company which focuses on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. The company's primary product is H.P. Acthar Gel, an injectable drug for the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. Questcor Pharmaceuticals was founded in September 1992 and is headquartered in Anaheim, CA.
Employees
Shareholders
| Mutual fund holders | 56.66% |
| Other institutional | 54.34% |
| Individual stakeholders | 37.30% |
Top Executives
| Don Matthew Bailey, MBA | President, Chief Executive Officer & Director |
| Stephen Lahue Cartt, MBA | Chief Operating Officer |
| Michael H. Mulroy | CFO, Secretary, CAO, Senior VP & General Counsel |
| Gary S. Hogge, PhD, DVM | Vice President-Medical Affairs |
| David J. Medeiros, MBA | Chief Technology Officer & Executive VP |
.
